RxDoctor Payments Data

Nitin Arora, MD

Family Medicine · Attica, NYNPI 1659682441

Payments from drug & device makers

$1,569in general payments, 2019–2025

Across 69 payments — averaging $22.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$663
  • AstraZeneca$186
  • Pfizer$169
  • AbbVie$141
  • Alkermes, Inc.$120
  • Lilly USA, LLC$51
  • plus $238 from 10 others

What the payments were for

  • Food & beverage$1,54899%
  • Education$211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,569 in reported general payments places this provider in the 70th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$59,009
Medicare patients
204
Services billed
525

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban87$30,325
JardianceEmpagliflozin46$16,360
TrulicityDulaglutide11$11,454
JanuviaSitagliptin Phosphate13$3,578
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$3,518
Atorvastatin Calcium183$2,344
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$1,890
Albuterol Sulfate HfaAlbuterol Sulfate39$1,601
Gabapentin114$1,317
Tamsulosin Hcl98$1,116
Mirtazapine39$1,039
Levetiracetam48$946
Pantoprazole Sodium115$857
Metoprolol Succinate88$851
Amlodipine Besylate144$840

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$169$30,32587 claims
Boehringer IngelheimJardiance$28$16,36046 claims
Lilly USA, LLCTrulicity$51$11,45411 claims
MerckJanuvia$40$3,57813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,321 family medicine providers in New York.

Other family medicine in Attica

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →